NCT06569524招募中2 期
A Double-blind, Placebo Randomized，Phase II Study to Evaluate the Efficacy and Safety of TQA2225/AP025 in Adults With Nonalcoholic Steatohepatitis (NASH)
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.53 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2023年9月14日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 120
- 试验地点
- 53
- 主要终点
- To determine the effect of 25 or 50mg TQA2225 vs matching placebo on liver biopsy (NASH CRN score) at Week 48 compared with Baseline
研究概览
简要总结
A randomized, double-blind, placebo-controlled Phase II study，to evaluate the efficacy and safety of TQA2225/AP025 in Patients With Non-Alcoholic Steatohepatitis (NASH)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be willing to participate in the study and provide written informed consent.
- •Male or female aged 18 ≤ age < 75 at the time of signing the informed consent.
- •Must have had prior liver biopsy within 180 days of randomization with fibrosis stage 1 to 3 and a NAS of ≥4 with at least a score of 1 in each of the lobular inflammation and ballooning degeneration.
- •Confirmation of ≥10% liver fat content on Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF).
- •Weight changes≤5% in the 6 weeks prior to randomization.
- •No qualitative change in dose for the drugs listed below:
- •Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months
- •Vitamin E (if at a dose ≥400 IU/day): for at least 6 months
- •Statins: for at least 3 months
- •Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 6 month after treatment discontinuation.
排除标准
- •Documented causes of chronic liver disease other than NASH
- •Type 1 diabetes or uncontrolled Type 2 diabetes defined as:Hemoglobin A1c ≥9% at screening，Fasting blood glucose≥13.9mmol/l
- •Uncontrolled hypertension at Screening (values ≥160/100 mm Hg)
- •History or presence of cirrhosis
- •Subjects with any type of active malignancy or a history of malignancy (except cervical cancer or non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma and papillary thyroid carcinoma) that has been cured for more than 5 years prior to the screening period;
- •Unable or unwilling to undergo liver biopsy according to research requirements.
- •History of weight loss surgery within 5 years (inclusive) prior to screening
- •A major surgery was performed 3 months prior to signing the Informed Consent Form (ICF), or planned during the study period.
- •Have experienced any bone trauma, fracture, or bone surgery within ≤ 2 months prior to screening.
- •When screening, according to the results of dual energy X-ray absorptiometry (DXA) examination, it meets the criteria for osteoporosis: T≤ -2.5
- •Recent history of drug abuse (defined as ≤ 2 years).
- •Patient participating in other clinical trials of drugs or medical devices within 3 months prior to screening.
- •Abnormal laboratory test values：ALT or AST >5 × ULN；Serum ALP≥2× ULN；eGFR<60mL/min；INR>1.3× ULN；platelets < LLN.
- •Pregnant or breastfeeding women.
- •Liver transplantation history or planned liver transplantation
- •Contraindications for MRI examination
- •Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.
研究组 & 干预措施
TQA2225/AP025 or TQA2225/AP025 Placebo 25mg
Experimental
TQA2225/AP025 or TQA2225/AP025 Placebo administered 25mg by subcutaneous (SC) injection weekly for 48 weeks
干预措施: TQA2225/AP025 or TQA2225/AP025 Placebo 25mg (Drug)
TQA2225/AP025 or TQA2225/AP025 Placebo 50mg
Experimental
TQA2225/AP025 or TQA2225/AP025 Placebo administered 50mg by subcutaneous (SC) injection weekly for 48 weeks
干预措施: TQA2225/AP025 or TQA2225/AP025 Placebo 50mg (Drug)
结局指标
主要结局
To determine the effect of 25 or 50mg TQA2225 vs matching placebo on liver biopsy (NASH CRN score) at Week 48 compared with Baseline
时间窗: After week 48 of TQA2225/AP025 treatment
1. Proportion with resolution of NASH (ballooning 0, inflammation 0,1) associated with at least 2-point reduction in NAFLD Activity Score (NAS) without worsening of fibrosis stage OR 2. Proportion with at least a 1-point improvement in fibrosis stage with no worsening of NAS
次要结局
- Adverse Events (AEs) and Serious Adverse Events (SAEs)(Baseline to week 48)
研究者
研究点 (53)
Loading locations...
相似试验
Unknown
2 期
A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19COVID-19NCT05381519Wuhan Institute of Biological Products Co., Ltd50
终止
2 期
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsCarcinoma, Non-Small-Cell LungNCT04323436Novartis Pharmaceuticals31
Unknown
2 期
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 InfectionCOVID-19 DiseaseNCT04969172Eli Sprecher, MD155
终止
2 期
Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary GeneralizationRefractory EpilepsyNCT04153175Cerebral Therapeutics LLC30
已完成
2 期
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac DiseaseCeliac DiseaseNCT013962139 Meters Biopharma, Inc.342